Histone modifications as a pathogenic mechanism of colorectal tumorigenesis

International Journal of Biochemistry and Cell Biology

Volumn 44, Issue 8, 2012, Pages 1276-1289

  Gargalionis, Antonios N ^a   Piperi, Christina ^a   Adamopoulos, Christos ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Colorectal cancer; Epigenetics; Histone acetylation; Methylation; Tumorigenesis

Indexed keywords

HISTONE; NONHISTONE PROTEIN;

CARCINOGENESIS; CHROMATIN; COLORECTAL CANCER; ENZYME REGULATION; EPIGENETICS; GENE EXPRESSION REGULATION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; PROTEIN PROCESSING; REVIEW; TUMOR SUPPRESSOR GENE;

ACETYLATION; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; HISTONES; HUMANS; METHYLATION; MODELS, BIOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84861478043     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2012.05.002     Document Type: Review

References (175)

1. Ahn CH, Yoo NJ, Lee JW, Lee SH. Absence of MLL3 mutations in colorectal carcinomas of Korean patients. APMIS 2007;115:859-60. (Pubitemid 47030110)
2. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998;95:6791-6.
3. Ashktorab H, Belgrave K, Hosseinkhah F, Brim H, Nouraie M, Takkikto M, et al. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Digestive Diseases and Sciences 2009;54:2109-17.
4. Ashktorab H, Schaffer AA, Daremipouran M, Smoot DT, Lee E, Brim H. Distinct genetic alterations in colorectal cancer. PLoS One 2010;5:e8879.
5. Avvakumov N, Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 2007;26:5395-407. (Pubitemid 47255922)
6. Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95. (Pubitemid 37443893)
7. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Research 2011;21:381-95.
8. Bannister AJ, Miska EA. Regulation of gene expression by transcription factor acetylation. Cellular and Molecular Life Sciences 2000;57:1184-92. (Pubitemid 30663476)
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 2006;5:769-84. (Pubitemid 44348499)
10. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE, et al. Tip60 is a nuclear hormone receptor coactivator. Journal of Biological Chemistry 1999;274:17599-604.
11. Bryan EJ, Jokubaitis VJ, Chamberlain NL, Baxter SW, Dawson E, Choong DY, et al. Mutation analysis of EP300 in colon, breast and ovarian carcinomas. International Journal of Cancer 2002;102:137-41. (Pubitemid 35168025)
12. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics 1999;21:103-7. (Pubitemid 29036293)
13. Campbell IG, Choong D, Chenevix-Trench G. No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer. Breast Cancer Research 2004;6:R366-71.
14. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43. (Pubitemid 35247314)
15. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nature Reviews Genetics 2009;10:295-304.
16. Chadwick RB, Jiang GL, Bennington GA, Yuan B, Johnson CK, Stevens MW, et al. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 2000;97:2662-7. (Pubitemid 30159228)
17. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001;293:1653-7. (Pubitemid 32807844)
18. Chen YX, Fang JY, Lu R, Qiu DK. Expression of p21(WAF1) is related to acetylation of histone H3 in total chromatin in human colorectal cancer. World Journal of Gastroenterology 2007;13:2209-13. (Pubitemid 46851158)
19. Cosgrove MS, Boeke JD, Wolberger C. Regulated nucleosome mobility and the histone code. Nature Structural & Molecular Biology 2004;11:1037-43. (Pubitemid 39453330)
20. Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of Oncology 2011 (Epub ahead of print).
21. Davis PK, Brackmann RK. Chromatin remodeling and cancer. Cancer Biology and Therapy 2003;2:22-9.
22. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Molecular Cancer Therapeutics 2009;8:1409-20.
23. Emterling A, Wallin A, Arbman G, Sun XF. Clinicopathological significance of microsatellite instability and mutated RIZ in colorectal cancer. Annals of Oncology 2004;15:242-6. (Pubitemid 38262622)
24. Enroth S, Rada-Iglesisas A, Andersson R, Wallerman O, Wanders A, Pahlman L, et al. Cancer associated epigenetic transitions identified by genome-wide histone methylation binding profiles in human colorectal cancer samples and paired normal mucosa. BMC Cancer 2011;11:450.
25. Evans PM, Zhang W, Chen X, Yang J, Bhakat KK, Liu C. Kruppel-like factor 4 is acetylated by p300 and regulates gene transcription via modulation of histone acetylation. Journal of Biological Chemistry 2007;282:33994-4002. (Pubitemid 350159428)
26. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
27. Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. Journal of Biomedicine and Biotechnology 2011;2011:475641.
28. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008;3:e2020.
29. Fluge O, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer 2009;101:1282-9.
30. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics 2005;37:391-400.
31. Francis NJ, Kingston RE, Woodcock CL. Chromatin compaction by a polycomb group protein complex. Science 2004;306:1574-7. (Pubitemid 39564957)
32. Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, Chan HM, et al. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Reports 2003;4:575-80. (Pubitemid 36939948)
33. Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 2011;30:3391-403.
34. Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Falth M, Sultmann H, et al. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One 2011;6:e21651.
35. Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emons G, et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes, Chromosomes and Cancer 2010;49:1024-34.
36. Gaughan L, Brady ME, Cook S, Neal DE, Robson CN. Tip60 is a co-activator specific for class I nuclear hormone receptors. Journal of Biological Chemistry 2001;276:46841-8.
37. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. Journal of Biological Chemistry 2002;277:25904-13. (Pubitemid 34967070)
38. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al. Mutations truncating the EP300 acetylase in human cancers. Nature Genetics 2000;24:300-3. (Pubitemid 30132203)
39. Ge X, Jin Q, Zhang F, Yan T, Zhai Q. PCAF acetylates {beta}-catenin and improves its stability. Molecular Biology of the Cell 2009;20:419-27.
40. Giannini R, Cavallini A. Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma. Anticancer Research 2005;25:4287-92. (Pubitemid 41665218)
41. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochemical Pharmacology 2007;74:659-71. (Pubitemid 47096639)
42. Godman CA, Joshi R, Tierney BR, Greenspan E, Rasmussen TP, Wang HW, et al. HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biology and Therapy 2008;7:1570-80.
43. Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, et al. Tip60 is a haploinsufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 2007;448:1063-7. (Pubitemid 47345581)
44. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52. (Pubitemid 27415209)
45. Gu W, Roeder RG. Activation of p53sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606. (Pubitemid 27357952)
46. Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. International Journal of Cancer 1993;55:498-505. (Pubitemid 23300605)
47. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nature Cell Biology 2004;6:731-40. (Pubitemid 39144478)
48. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
49. Hanigan CL, Van Engeland M, De Bruine AP, Wouters KA, Weijenberg MP, Eshleman JR, et al. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 2008;135:1654-64, e2.
50. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. International Journal of Cancer 2011;128:574-86.
51. Heerdt BG, Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Research 1994;54:3288-93.
52. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences of the United States of America 1998;95:6870-5. (Pubitemid 28278073)
53. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New England Journal of Medicine 2003;349:2042-54. (Pubitemid 37448928)
54. Higashijima J, Kurita N, Miyatani T, Yoshikawa K, Morimoto S, Nishioka M, et al. Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncology Reports 2011;26:343-8.
55. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death and Differentiation 2005;12:395-404. (Pubitemid 40520691)
56. Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T, et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. Journal of Biological Chemistry 2010;285:9636-41.
57. Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Current Drug Targets 2011;12:1925-56.
58. Ionov Y, Matsui S, Cowell JK. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proceedings of the National Academy of Sciences of the United States of America 2004;101:1273-8. (Pubitemid 38182679)
59. Ishihama K, Yamakawa M, Semba S, Takeda H, Kawata S, Kimura S, et al. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. Journal of Clinical Pathology 2007;60:1205-10. (Pubitemid 350084539)
60. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23:4225-31. (Pubitemid 38758588)
61. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA: A Cancer Journal for Clinicians 2011;61:69-90.
62. Jiang GL, Huang S. Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers. Cancer Research 2001;61:1796-8. (Pubitemid 32691986)
63. Jin B, Yao B, Li JL, Fields CR, Delmas AL, Liu C, et al. DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer. Cancer Research 2009;69:7412-21.
64. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target. Cancer Cell 2003;4:13-8. (Pubitemid 36904157)
65. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92. (Pubitemid 46273572)
66. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genetics 1998;19:187-91. (Pubitemid 28248804)
67. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. Journal of Biological Chemistry 2009;284:18210-7.
68. Kang MY, Lee BB, Kim YH, Chang DK, Kyu Park S, Chun HK, et al. Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer. International Journal of Cancer 2007;121:2192-7.
69. Karagiannis TC, El-Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 2006;25:3885-93. (Pubitemid 43990743)
70. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 2011;147:382-95.
71. Keshet I, Schlesinger Y, Farkash S, Rand E, Hecht M, Segal E, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nature Genetics 2006;38:149-53. (Pubitemid 43177227)
72. Kim YR, Lee BK, Park RY, Nguyen NT, Bae JA, Kwon DD, et al. Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer 2010;10:197.
73. Kim YS, Tsao D, Siddiqui B, Whitehead JS, Arnstein P, Bennett J, et al. Effects of sodium butyrate and dimethylsulfoxide on biochemical properties of human colon cancer cells. Cancer 1980;45:1185-92. (Pubitemid 10125129)
74. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes and Development 2004;18:1592-605. (Pubitemid 38868910)
75. Kloosterman WP, Hoogstraat M, Paling O, Tavakoli-Yaraki M, Renkens I, Vermaat JS, et al. Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. Genome Biology 2011;12:R103.
76. Knudson AG. Two genetic hits (more or less) to cancer. Nature Reviews Cancer 2001;1:157-62. (Pubitemid 33741891)
77. Kodach LL, Jacobs RJ, Heijmans J, van Noesel CJ, Langers AM, Verspaget HW, et al. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 2010;31:1567-75.
78. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Research 2011;71:6320-6.
79. Konishi K, Issa JP. Targeting aberrant chromatin structure in colorectal carcinomas. Cancer Journal 2007;13:49-55.
80. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705. (Pubitemid 46273577)
81. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nature Reviews Cancer 2007;7:823-33. (Pubitemid 350006257)
82. Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, Nagayasu T, Shibuya M, et al. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Research 2007;67:10759-65. (Pubitemid 350145903)
83. Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proceedings of the National Academy of Sciences of the United States of America 2005;102:1859-64. (Pubitemid 40261977)
84. Kwon MJ, Kim SS, Choi YL, Jung HS, Balch C, Kim SH, et al. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010;31:974-83.
85. Lee CC, Chen WS, Chen CC, Chen LL, Lin YS, Fan CS, et al. TCF12 protein functions as transcriptional repressor of E-cadherin, and its overexpression is correlated with metastasis of colorectal cancer. Journal of Biological Chemistry 2012;287:2798-809.
86. Lee DY, Teyssier C, Strahl BD, Stallcup MR. Role of protein methylation in regulation of transcription. Endocrine Reviews 2005;26:147-70.
87. Li Q, Chen H. Transcriptional silencing of N-Myc downstream-regulated gene 1 (NDRG1) in metastatic colon cancer cell line SW620. Clinical and Experimental Metastasis 2011;28:127-35.
88. Liu Y, Hong Y, Zhao Y, Ismail TM, Wong Y, Eu KW, et al. Histone H3 (lys-9) deacetylation is associated with transcriptional silencing of E-cadherin in colorectal cancer cell lines. Cancer Investigation 2008;26:575-82. (Pubitemid 351918577)
89. Lleonart ME, Vidal F, Gallardo D, Diaz-Fuertes M, Rojo F, Cuatrecasas M, et al. New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. Oncology Reports 2006;16:603-8.
90. Magdinier F, Wolffe AP. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proceedings of the National Academy of Sciences of the United States of America 2001;98:4990-5. (Pubitemid 32397070)
91. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008a;3:28-37. (Pubitemid 351540961)
92. Mariadason JM. Making sense of HDAC2 mutations in colon cancer. Gastroenterology 2008b;135:1457-9.
93. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nature Reviews Molecular Cell Biology 2005;6:838-49. (Pubitemid 41568733)
94. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO Journal 2000;19:662-71. (Pubitemid 30093739)
95. Mathioudaki K, Papadokostopoulou A, Scorilas A, Xynopoulos D, Agnanti N, Talieri M. The PRMT1 gene expression pattern in colon cancer. British Journal of Cancer 2008;99:2094-9.
96. Mattera L, Escaffit F, Pillaire MJ, Selves J, Tyteca S, Hoffmann JS, et al. The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways. Oncogene 2009;28:1506-17.
97. McGarvey KM, Greene E, Fahrner JA, Jenuwein T, Baylin SB. DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Research 2007;67:5097-102. (Pubitemid 46997244)
98. Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. European Journal of Surgical Oncology 2005;31:376-80. (Pubitemid 40521303)
99. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Human Molecular Genetics 2007;16(Spec No. 1):R28-49.
100. Mossman D, Scott RJ. Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation. PLoS One 2011;6:e23127.
101. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong JM, et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996;12:1565-9. (Pubitemid 26132043)
102. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncology Reports 2007;18:769-74.
103. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. Journal of Biological Chemistry 1997;272:22199-206. (Pubitemid 27382850)
104. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9. (Pubitemid 28269714)
105. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Research 2002;62:6456-61. (Pubitemid 35364106)
106. Nishioka K, Rice JC, Sarma K, Erdjument-Bromage H, Werner J, Wang Y, et al. PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Molecular Cell 2002;9:1201-13. (Pubitemid 34722300)
107. Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, et al. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Modern Pathology 2009;22:922-32.
108. Ou CY, LaBonte MJ, Manegold PC, So AY, Ianculescu I, Gerke DS, et al. A coactivator role of CARM1 in the dysregulation of beta-catenin activity in colorectal cancer cell growth and gene expression. Molecular Cancer Research 2011;9:660-70.
109. Ozdag H, Batley SJ, Forsti A, Iyer NG, Daigo Y, Boutell J, et al. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. British Journal of Cancer 2002;87:1162-5. (Pubitemid 35422720)
110. Ozdag H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L, et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006;7:90.
111. Pancione M, Sabatino L, Fucci A, Carafa V, Nebbioso A, Forte N, et al. Epigenetic silencing of peroxisome proliferator-activated receptor gamma is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One 2010;5:e14229.
112. Papadokostopoulou A, Mathioudaki K, Scorilas A, Xynopoulos D, Ardavanis A, Kouroumalis E, et al. Colon cancer and protein arginine methyltransferase 1 gene expression. Anticancer Research 2009;29:1361-6.
113. Pelaez IM, Kalogeropoulou M, Ferraro A, Voulgari A, Pankotai T, Boros I, et al. Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma cells. International Journal of Biochemistry and Cell Biology 2010;42:911-20.
114. Pena C, Garcia JM, Garcia V, Silva J, Dominguez G, Rodriguez R, et al. The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. International Journal of Cancer 2006;119:2098-104.
115. Peterson CL, Laniel MA. Histones and histone modifications. Current Biology 2004;14:R546-51.
116. Piao Z, Fang W, Malkhosyan S, Kim H, Horii A, Perucho M, et al. Frequent frameshift mutations of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability. Cancer Research 2000;60:4701-4.
117. Pogribny IP, Ross SA, Tryndyak VP, Pogribna M, Poirier LA, Karpinets TV. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 2006;27:1180-6. (Pubitemid 43985433)
118. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genetics 2006;2:e40.
119. Rada-Iglesias A, Enroth S, Andersson R, Wanders A, Pahlman L, Komorowski J, et al. Histone H3 lysine 27 trimethylation in adult differentiated colon associated to cancer DNA hypermethylation. Epigenetics 2009;4:107-13.
120. Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. Cell Death & Disease 2011;2:e204.
121. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977;268:462-4.
122. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nature Genetics 2006;38:566-9.
123. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nature Genetics 2000;25: 269-77. (Pubitemid 30437311)
124. Saif MW, Chu E. Biology of colorectal cancer. Cancer Journal 2010;16:196-201.
125. Sakuraba K, Yasuda T, Sakata M, Kitamura YH, Shirahata A, Goto T, et al. Downregulation of Tip60 gene as a potential marker for the malignancy of colorectal cancer. Anticancer Research 2009;29:3953-5.
126. Sakurada K, Furukawa T, Kato Y, Kayama T, Huang S, Horii A. RIZ, the retinoblastoma protein interacting zinc finger gene, is mutated in genetically unstable cancers of the pancreas, stomach, and colorectum. Genes, Chromosomes and Cancer 2001;30:207-11. (Pubitemid 32044603)
127. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language. Cell 2011;146:353-8.
128. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. European Journal of Cancer 2005;41:2381-402. (Pubitemid 41540617)
129. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nature Genetics 2007;39:232-6. (Pubitemid 46184355)
130. Schnekenburger M, Diederich M. Epigenetics offer new horizons for colorectal cancer prevention. Current Colorectal Cancer Reports 2012;8:66-81.
131. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes and Development 2004;18:1251-62. (Pubitemid 38720593)
132. Schwartz B, Avivi-Green C, Polak-Charcon S. Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells. Molecular and Cellular Biochemistry 1998;188:21-30. (Pubitemid 28493314)
133. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians 2012;62:10-29.
134. Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes and Development 2006;20:586-600. (Pubitemid 43345324)
135. Silva FP, Hamamoto R, Kunizaki M, Tsuge M, Nakamura Y, Furukawa Y. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene 2008;27:2686-92. (Pubitemid 351581465)
136. Sinkkonen L, Hugenschmidt T, Berninger P, Gaidatzis D, Mohn F, Artus-Revel CG, et al. MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nature Structural & Molecular Biology 2008;3:259-67. (Pubitemid 351654045)
137. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74. (Pubitemid 44571966)
138. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nature Reviews Cancer 2006;11:846-56. (Pubitemid 44629896)
139. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Molecular Carcinogenesis 2008;47:137-47. (Pubitemid 351231442)
140. Stark GR, Wang Y, Lu T. Lysine methylation of promoter-bound transcription factors and relevance to cancer. Cell Research 2011;3:375-80.
141. Steele-Perkins G, Fang W, Yang XH, Van Gele M, Carling T, Gu J, et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes and Development 2001;15:2250-62. (Pubitemid 32843837)
142. Sun WJ, Zhou X, Zheng JH, Lu MD, Nie JY, Yang XJ, et al. Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis. Acta Biochimica et Biophysica Sinica (Shanghai) 2012;44:80-91.
143. Sun Y, Qiao L, Zou B, Xia HH, Gu Q, Ma J, et al. Interactions between XIAP associated factor 1 and a nuclear co-activator, CBP, in colon cancer cells. Digestion 2008;77:79-86. (Pubitemid 351556384)
144. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 2006;9:199-207. (Pubitemid 43357946)
145. Tachibana M, Matsumura Y, Fukuda M, Kimura H, Shinkai Y. G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription. EMBO Journal 2008;27:2681-90.
146. Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Science 2011;102:1298-305.
147. Tamagawa H, Oshima T, Shiozawa M, Morinaga S, Nakamura Y, Yoshihara M, et al. The global histone modification pattern correlates with overall survival. Oncology Reports 2012;27:637-42.
148. Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, Noda T, et al. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Molecular Cancer Research 2009;7:557-69.
149. Taubert S, Gorrini C, Frank SR, Parisi T, Fuchs M, Chan HM, et al. E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Molecular and Cellular Biology 2004;24:4546-56. (Pubitemid 44109137)
150. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011;147:344-57.
151. Ting AH, Suzuki H, Cope L, Schuebel KE, Lee BH, Toyota M, et al. A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells. Cancer Research 2008;68:2570-5. (Pubitemid 351556253)
152. Tsuge M, Hamamoto R, Silva FP, Ohnishi Y, Chayama K, Kamatani N, et al. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5′ flanking region of SMYD3 is a risk factor for human cancers. Nature Genetics 2005;37:1104-7. (Pubitemid 41486663)
153. Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemotherapy and Pharmacology 2007;60:275-83. (Pubitemid 46742543)
154. Uemura M, Yamamoto H, Takemasa I, Mimori K, Hemmi H, Mizushima T, et al.
155. Vakoc CR, Wen YY, Gibbs RA, Johnstone CN, Rustgi AK, Blobel GA. Low frequency of MLL3 mutations in colorectal carcinoma. Cancer Genetics and Cytogenetics 2009;189:140-1.
156. van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. Journal of Clinical Oncology 2011;29:1382-91.
157. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
158. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-4. (Pubitemid 43255707)
159. Vlaicu SI, Tegla CA, Cudrici CD, Fosbrink M, Nguyen V, Azimzadeh P, et al. Epigenetic modifications induced by RGC-32 in colon cancer. Experimental and Molecular Pathology 2010;88:67-76.
160. Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World Journal of Gastroenterology 2010;16:2421-7.
161. Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, part I: covalent histone modifications. Trends in Molecular Medicine 2007;13:363-72. (Pubitemid 47385381)
162. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, et al. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. European Journal of Cancer 2011a;47:1946-54.
163. Watanabe Y, Castoro RJ, Kim HS, North B, Oikawa R, Hiraishi T, et al. Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS One 2011b;6:e23320.
164. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clinical Cancer Research 2008;14:1669-77. (Pubitemid 351469450)
165. Wilson AJ, Velcich A, Arango D, Kurland AR, Shenoy SM, Pezo RC, et al. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Research 2002;62:6006-10. (Pubitemid 35244443)
166. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. Journal of Biological Chemistry 2006;281:13548-58. (Pubitemid 43855268)
167. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Molecular Biology of the Cell 2008;19:4062-75.
168. Wong CS, Sengupta S, Tjandra JJ, Gibson PR. The influence of specific luminal factors on the colonic epithelium: high-dose butyrate and physical changes suppress early carcinogenic events in rats. Diseases of the Colon and Rectum 2005;48:549-59. (Pubitemid 40767879)
169. Xi Y, Formentini A, Nakajima G, Kornmann M, Ju J. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncology Reports 2008;19:257-62. (Pubitemid 351176158)
170. Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Research 2004;32:959-76.
171. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307:269-73. (Pubitemid 40116244)
172. Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ, et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nature Structural & Molecular Biology 2009;16:304-11.
173. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-63. (Pubitemid 38610247)
174. Zimmermann S, Kiefer F, Prudenziati M, Spiller C, Hansen J, Floss T, et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Research 2007;67:9047-54. (Pubitemid 47535889)
175. Zuo X, Morris JS, Shureiqi I. Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells. Journal of Biological Chemistry 2008;283:31341-7.